文献速递青光眼角膜与眼表疾病

含与不含BAK防腐剂的慢性局部抗青光眼治疗眼表的泪液神经介质

Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives.
PubMed 文献 · Br J Ophthalmol · 2019-08-05

本比较性、开放标签、横断面研究纳入使用抗青光眼药物超过6个月且含BAK(第1组)或不含BAK(第2组)的患者及对照组,检测泪液神经肽(VIP、NPY、CGRP、SP、NGF)并行眼表评估与共聚焦中央角膜上皮下神经纤维层成像。结果显示与对照组相比,泪液SP和NGF升高(p<0.01),CGRP降低(p=0.03),VIP和NPY降低(p<0.01);含BAK与不含BAK两组间泪液神经肽水平及中央角膜上皮下神经纤维层密度无显著差异。

要点

  • 慢性局部抗青光眼治疗眼与对照组相比泪液SP和NGF升高(p<0.01),CGRP降低(p=0.03),VIP和NPY降低(p<0.01)。
  • 含BAK与不含BAK的抗青光眼治疗两组间泪液神经肽水平及中央角膜上皮下神经纤维层密度无显著差异。
  • 泪液神经肽水平与临床眼表测试及中央角膜上皮下神经纤维层密度之间未见相关性。

核心结论

  • 研究分析提示慢性局部降眼压治疗眼与对照组相比泪液神经肽水平发生改变。
  • 含BAK防腐剂与不含BAK的抗青光眼治疗之间泪液神经肽水平及中央角膜上皮下神经纤维层密度无显著差异。

研究设计与样本

  • 比较性、开放标签、横断面研究,纳入使用抗青光眼药物超过6个月且含BAK者(第1组)、不含BAK者(第2组)及对照组。
  • 共评估153眼,第1组82眼(41例患者,平均年龄48±14.5岁),第2组71眼(36例患者,平均年龄43.11±15岁),对照组n=30(平均年龄29.33±5.7岁)。
  • 第1组和第2组平均用药时长分别为10.05±2.0个月和9.67±2.3个月。
  • 检测泪液神经肽(ELISA)、眼表评估测试(泪膜破裂时间、Schirmer试验、角膜和结膜染色评分)及共聚焦中央角膜上皮下神经纤维层成像。

主要发现

  • 与对照组相比,泪液SP和NGF升高(p<0.01),CGRP降低(p=0.03),VIP和NPY降低(p<0.01)。
  • 含BAK组与不含BAK组之间泪液神经肽水平相当:SP(p=0.1)、NGF(p=0.33)、CGRP(p=1)、VIP(p=0.87)、NPY(p=0.83)。
  • 含BAK组与不含BAK组之间中央角膜上皮下神经纤维层密度相当(p=0.09)。
  • 泪液神经肽水平与临床测试及中央角膜上皮下神经纤维层密度之间未见相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate tear neuropeptides (NPs) (vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP), substance P (SP), nerve growth factor (NGF)) in chronic ocular topical hypotensive therapy with and without benzalkonium chloride (BAK) preservative. METHODS: A comparative, open label, cross-sectional study of patients using antiglaucoma medications for >6 months with BAK (group I), without BAK (group II) and controls was done. Tear NPs (ELISA), ocular surface evaluation tests (tear breakup time (TBUT), Schirmer's test, corneal and conjunctival staining score) and confocal central corneal subbasal nerve fibre layer (SBNFL) imaging was done. RESULTS: Of 153 eyes evaluated, group 1 (82 eyes (41 patients; mean age 48±14.5 years)) and group 2 (71 eyes (36 patients; mean age 43.11±15 years)) were on therapy for a mean duration of 10.05±2.0 and 9.67±2.3 months, respectively. Tear analysis showed elevated SP and NGF (p<0.01); decreased CGRP (p=0.03), VIP and NPY (p<0.01) compared with controls (n=30, mean age 29.33±5.7 years). Tear NP levels (SP (p=0.1), NGF (p=0.33), CGRP (p=1), VIP (p=0.87), NPY (p=0.83)) and SBNFL (p=0.09) were comparable in both groups. There was no correlation seen between tear NP levels and clinical tests and SBNFL. CONCLUSION: Our study analysis points towards altered tear NP levels in eyes on chronic topical hypotensive therapy in comparison with controls with no significant difference in tear NP levels and central corneal SBNFL density between the BAK preservative and BAK-free antiglaucoma therapy.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Murugesan V, Dwivedi R, Saini M, et al. Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives. Br J Ophthalmol. 2019. PMID: 31383648. doi:10.1136/bjophthalmol-2019-314234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。